References

  1. American Heart Association. Heart Disease and Stroke Statistics—2007 Update. Dallas, TX American Heart Association: 2007.
  2. Albers GW. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients? Neurology. 2000;54:1022-1028.
  3. Coull AJ, Lovett JK, Rothwell PM, on behalf of the Oxford Vascular Study. Population based study of early risk of stroke after transient ischemic attack or minor stroke: implications for public education and organization of services. BMJ [serial online]. January 26, 2004; doi:10.1136/bmj.37991.635266.44
  4. National Stroke Association. Symptoms. http://www.stroke.org/site/PageServer?pagename=SYMP. Accessed on March 25, 2007.
  5. Ryan M, Combs G, Penix L. Preventing strokes in patients with transient ischemic attacks. Am Fam Phys. 1999;60:2329-2342.
  6. Kleindorfer D, Penagos P, Pancioli A, et al. Incidence and short term prognosis of transient ischemic attack in a population based study. Stroke. 2005;36:720-724.
  7. Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2006;60:301-313.
  8. Sacco RL, Adams R. Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke. 2006;37:577-617.
  9. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl3):483S-512S.
  10. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
  11. Sacco RL, Sivenius J, Diener HC. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol. 2005;62:403-408.
  12. Lipton RB, Bigal ME, Kolodner KB, et al. Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination. Neurology. 2004;63:1099-1101.
  13. American Heart Association. Heart and Stroke Facts. Dallas, TX: American Heart Association; 2003.
  14. Aggrenox® (aspirin/extended-release dipyridamole) Prescribing Information.
  15. Data on File, Boehringer Ingelheim Pharmaceuticals, Inc.
  16. Derendorf H, VanderMaelen CP, Brickl RS, et al. Dipyridamole bioavailability in subjects with reduced gastric acidity. J. Clin. Pharmacol. 2005;45:845-850. 
  17. Green LK, Graham DY. Gastritis in the elderly. Gastroenterol Clin North Am. 1990;19:273-292.
  18. Hurwitz A, Brady DA, Schaal SE, et al. Gastric acidity in older adults. JAMA. 1997;278:659-662.
  19. Eisert WG. Dipyridamole. In: Michelson AD, ed. Platelets. San Diego, CA; Academic Press; 2002:803-815.
  20. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register. 1998;63(205):56802-56819 (codified at 21 CFR §343).
  21. Diener HC, Sacco RL, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes trial (PRoFESS). Cerebrovasc Dis. 2007;23:368-380.